Clinical Trials

Ra Pharmaceuticals is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of complement-mediated diseases. We are committed to the discovery and development of innovative medicines to treat diseases with unmet medical needs. As part of this commitment, we sponsor and support medical research through clinical trials.

To learn more about Ra Pharmaceuticals’ clinical trials, please click here.

If you have questions about our clinical trials, please contact a member of the Ra Pharmaceuticals team.

Email: trials@rapharma.com

Telephone: (617) 401-4060

Ra Pharma Policy on Expanded Access

Ra Pharmaceuticals, Inc. is committed to developing new therapies for treating patients with rare diseases. We believe establishing the risk-benefit profile of our drug products through adequate and well-controlled clinical trials, which are designed to gain an understanding of the safety and efficacy of the therapy in a specific population, followed by thorough regulatory review by the U.S. Food and Drug Administration, is the best path to potential regulatory approval and subsequent access for the greatest number of patients. Patients in need of an investigational product that has not yet been approved or commercialized are therefore encouraged to participate in one of our clinical trials.

In rare cases, physicians treating patients with serious, life-threatening diseases for which no approved therapy is available and who cannot participate in any clinical study may seek expanded access to investigational products. Expanded access programs, sometimes referred to as “compassionate use” or “early access” programs, are designed to make an investigational therapy available for use outside a clinical trial when the primary purpose is to diagnose, prevent, or treat a serious, life-threatening condition in a patient.

At the present time, we do not offer an expanded access program for any of our investigational agents and therefore participation in one of our clinical trials is the most appropriate way to access our products in development. If you have additional questions, please speak with your physician or contact medinfo@rapharma.com We anticipate acknowledging receipt of requests sent to this e-mail within seven business days.

In line with the 21st Century Cures Act, Ra Pharma reserves the right to revise this policy at any time.